Iron deficits have been reported as a risk factor for psychotic spectrum disorders (PSD). However, examinations of brain iron in PSD remain limited. The current study employed quantitative MRI to examine iron content in several iron-rich subcortical structures in 49 young adult individuals with PSD (15 schizophrenia, 17 schizoaffective disorder, and 17 bipolar disorder with psychotic features) compared with 35 age-matched healthy controls (HC). A parametric approach based on a two-pool magnetization transfer model was applied to estimate longitudinal relaxation rate (R1), which reflects both iron and myelin, and macromolecular proton fraction (MPF), which is specific to myelin. To describe iron content, a synthetic effective transverse relaxation rate (R2*) was modeled using a linear fitting of R1 and MPF. PSD patients compared to HC showed significantly reduced R1 and synthetic R2* across examined regions including the pallidum, ventral diencephalon, thalamus, and putamen areas. This finding was primarily driven by decreases in the subgroup with schizophrenia, followed by schizoaffective disorder. No significant group differences were noted for MPF between PSD and HC while for regional volume, significant reductions in patients were only observed in bilateral caudate, suggesting that R1 and synthetic R2* reductions in schizophrenia and schizoaffective patients likely reflect iron deficits that either occur independently or precede structural and myelin changes. Subcortical R1 and synthetic R2* were also found to be inversely related to positive symptoms within the PSD group and to schizotypal traits across the whole sample. These findings that decreased iron in subcortical regions are associated with PSD risk and symptomatology suggest that brain iron deficiencies may play a role in PSD pathology and warrant further study.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Med. 2018;48:229–44.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.
Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: A meta-analysis. Schizophrenia Res. 2010;117:1–12.
van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21:547–53.
Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat. 1992;144:235–57.
Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41–51.
Ogg RJ, Steen RG. Age-related changes in brain T1 are correlated with iron concentration. Magn Reson Med. 1998;40:749–53.
Larsen B, Bourque J, Moore TM, Adebimpe A, Calkins ME, Elliott MA, et al. Longitudinal Development of Brain Iron Is Linked to Cognition in Youth. J Neurosci. 2020;40:1810–8.
Peterson ET, Kwon D, Luna B, Larsen B, Prouty D, De Bellis MD, et al. Distribution of brain iron accrual in adolescence: Evidence from cross-sectional and longitudinal analysis. Hum Brain Mapp. 2019;40:1480–95.
Pivina L, Semenova Y, Doşa MD, Dauletyarova M, Bjørklund G. Iron Deficiency, Cognitive Functions, and Neurobehavioral Disorders in Children. J Mol Neurosci. 2019;68:1–10.
Spence H, McNeil CJ, Waiter GD. The impact of brain iron accumulation on cognition: A systematic review. PloS one. 2020;15:e0240697–e0240697.
Lozoff B. Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J Nutr. 2011;141:740S–746S.
Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem. 2014;25:1101–7.
Georgieff MK. Iron assessment to protect the developing brain. Am J Clin Nutr. 2017;106:1588S–1593S.
Hect JL, Daugherty AM, Hermez KM, Thomason ME. Developmental variation in regional brain iron and its relation to cognitive functions in childhood. Developmental Cogn Neurosci. 2018;34:18–26.
Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. Glia. 2009;57:467–78.
Haroutunian V, Katsel P, Roussos P, Davis K, Altshuler L, Bartzokis G. Myelination, oligodendrocytes, and serious mental illness. Glia. 2014;62:1856–77.
Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31:361–70.
Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161:398–413.
Insel BJ, Schaefer CA, McKeague IW, Susser ES, Brown AS. Maternal iron deficiency and the risk of schizophrenia in offspring. Arch Gen Psychiatry. 2008;65:1136–44.
Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson imaging. 2005;23:1–25.
Fukunaga M, Li TQ, van Gelderen P, de Zwart JA, Shmueli K, Yao B, et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci USA. 2010;107:3834–9.
Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, et al. Quantitative MR Imaging of Brain Iron: A Postmortem Validation Study. Radiology. 2010;257:455–62.
Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage. 2012;62:1593–9.
Deistung A, Schäfer A, Schweser F, Biedermann U, Turner R, Reichenbach JR. Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. NeuroImage. 2013;65:299–314.
Xu M, Guo Y, Cheng J, Xue K, Yang M, Song X, et al. Brain iron assessment in patients with First-episode schizophrenia using quantitative susceptibility mapping. NeuroImage: Clin. 2021;31:102736.
Sorensen HJ, Nielsen PR, Pedersen CB, Mortensen PB. Association between prepartum maternal iron deficiency and offspring risk of schizophrenia: population-based cohort study with linkage of Danish national registers. Schizophrenia Bull. 2011;37:982–7.
Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Association between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. BMC Psychiatry. 2013;13:161.
Lee H-S, Chao H-H, Huang W-T, Chen SC-C, Yang H-Y. Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. BMC Psychiatry. 2020;20:216.
Saghazadeh A, Mahmoudi M, Shahrokhi S, Mojarrad M, Dastmardi M, Mirbeyk M, et al. Trace elements in schizophrenia: a systematic review and meta-analysis of 39 studies (N = 5151 participants). Nutr Rev. 2020;78:278–303.
Kim SW, Stewart R, Park WY, Jhon M, Lee JY, Kim SY, et al. Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder. Nutrients. 2018;10:1707.
Casanova MF, Waldman IN, Kleinman JE. A postmortem quantitative study of iron in the globus pallidus of schizophrenic patients. Biol Psychiatry. 1990;27:143–9.
Kornhuber J, Lange KW, Kruzik P, Rausch WD, Gabriel E, Jellinger K, et al. Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. Biol Psychiatry. 1994;36:31–34.
Lange KW, Kornhuber J, Kruzik P, Rausch WD, Gabriel E, Jellinger K, et al. Brain iron and schizophrenia. In: Riederer P, Youdim MBH, editors. Iron in Central Nervous System Disorders. Vienna: Springer; 1993. pp 37–43.
Stevens JR. Neuropathology of schizophrenia. Arch Gen Psychiatry. 1982;39:1131–9.
Stuber C, Morawski M, Schafer A, Labadie C, Wahnert M, Leuze C, et al. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. NeuroImage. 2014;93:95–106.
Khodanovich M, Pishchelko A, Glazacheva V, Pan E, Akulov A, Svetlik M, et al. Quantitative Imaging of White and Gray Matter Remyelination in the Cuprizone Demyelination Model Using the Macromolecular Proton Fraction. Cells 2019;8:1204.
Underhill HR, Rostomily RC, Mikheev AM, Yuan C, Yarnykh VL. Fast bound pool fraction imaging of the in vivo rat brain: association with myelin content and validation in the C6 glioma model. NeuroImage. 2011;54:2052–65.
Yarnykh VL. Fast macromolecular proton fraction mapping from a single off-resonance magnetization transfer measurement. Magn Reson Med. 2012;68:166–78.
Samsonov AA, Alexander AL, Mossahebi P, Wu YC, Duncan ID, Field AS. Quantitative MR imaging of two-pool magnetization transfer model parameters in myelin mutant shaking pup. NeuroImage. 2012;62:1390–8.
Yarnykh VL, Krutenkova EP, Aitmagambetova G, Repovic P, Mayadev A, Qian P, et al. Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. AJNR Am J Neuroradiol. 2018;39:618–25.
Callaghan MF, Helms G, Lutti A, Mohammadi S, Weiskopf N. A general linear relaxometry model of R1 using imaging data. Magn Reson Med. 2015;73:1309–14.
Kendler KS, Lieberman JA, Walsh D. The Structured Interview for Schizotypy (SIS): a preliminary report. Schizophrenia Bull. 1989;15:559–71.
Walter EE, Fernandez F, Snelling M, Barkus E. Genetic consideration of schizotypal traits: A review. Front Psychol. 2016;7:1769.
Yarnykh VL. Time-efficient, high-resolution, whole brain three-dimensional macromolecular proton fraction mapping. Magn Reson Med. 2016;75:2100–6.
Mossahebi P, Samsonov AA. Rapid and accurate variable flip angle T1 mapping with correction of on-resonance MT effects. In: Proceedings of the ISMRM. MelBourne: ISMRM annual Meeting; 2012. pp 4267.
Kellner E, Dhital B, Kiselev VG, Reisert M. Gibbs-ringing artifact removal based on local subvoxel-shifts. Magn Reson Med. 2016;76:1574–81.
Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143–55.
Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17:825–41.
Veraart J, Novikov DS, Christiaens D, Ades-Aron B, Sijbers J, Fieremans E. Denoising of diffusion MRI using random matrix theory. NeuroImage. 2016;142:394–406.
Veraart J, Fieremans E, Novikov DS. Diffusion MRI noise mapping using random matrix theory. Magn Reson Med. 2016;76:1582–93.
Mossahebi P, Yarnykh VL, Samsonov A. Analysis and correction of biases in cross-relaxation MRI due to biexponential longitudinal relaxation. Magn Reson Med. 2014;71:830–8.
Samsonov AA, Mossahebi P, Anderson A, Velikina JV, Johnson KM, Johnson SC, et al. High Resolution, Motion Corrected Mapping of Macromolecular Proton Fraction (MPF). Clinically Acceptable Time Using 3D Undersampled Radials. In: Proceedings of the ISMRM. Milan: ISMRM annual Meeting; 2014. pp 3337.
Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.
Womer FY, Wang L, Alpert KI, Smith MJ, Csernansky JG, Barch DM, et al. Basal ganglia and thalamic morphology in schizophrenia and bipolar disorder. Psychiatry Res. 2014;223:75–83.
Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006;8:118–27.
Fortin JP, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Cook PA, et al. Harmonization of cortical thickness measurements across scanners and sites. NeuroImage. 2018;167:104–20.
Fortin JP, Parker D, Tunc B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion tensor imaging data. NeuroImage. 2017;161:149–70.
Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67:1–48.
Harkins KD, Xu J, Dula AN, Li K, Valentine WM, Gochberg DF, et al. The microstructural correlates of T1 in white matter. Magn Reson Med. 2016;75:1341–5.
Rooney WD, Johnson G, Li X, Cohen ER, Kim SG, Ugurbil K, et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo. Magn Reson Med. 2007;57:308–18.
Tukey JW. Exploratory data analysis. Massachusetts: Addison-Wesley; 1977.
Lorio S, Kherif F, Ruef A, Melie-Garcia L, Frackowiak R, Ashburner J, et al. Neurobiological origin of spurious brain morphological changes: A quantitative MRI study. Hum Brain Mapp. 2016;37:1801–15.
Lorio S, Lutti A, Kherif F, Ruef A, Dukart J, Chowdhury R, et al. Disentangling in vivo the effects of iron content and atrophy on the ageing human brain. Neuroimage. 2014;103:280–9.
Callaghan MF, Mohammadi S, Weiskopf N. Synthetic quantitative MRI through relaxometry modelling. NMR Biomed. 2016;29:1729–38.
Vymazal J, Urgosik D, Bulte JW. Differentiation between hemosiderin- and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol (Noisy-le-Gd). 2000;46:835–42.
Lee J, Shmueli K, Kang BT, Yao B, Fukunaga M, van Gelderen P, et al. The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. NeuroImage. 2012;59:3967–75.
Tamminga CA, Pearlson G, Keshavan M, Sweeney J, Clementz B, Thaker G. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophrenia Bull. 2014;40:S131–137.
Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers. Curr Pharm Des. 2020;26:191–200.
McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33.
Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA psychiatry. 2017;74:1206–13.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.
Bianco LE, Wiesinger J, Earley CJ, Jones BC, Beard JL. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J Neurochem. 2008;106:205–15.
Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharm Biochem Behav. 2001;69:409–18.
Beard JL, Chen Q, Connor J, Jones BC. Altered monamine metabolism in caudate-putamen of iron-deficient rats. Pharm Biochem Behav. 1994;48:621–4.
Larsen B, Olafsson V, Calabro F, Laymon C, Tervo-Clemmens B, Campbell E, et al. Maturation of the human striatal dopamine system revealed by PET and quantitative MRI. Nat Commun. 2020;11:846.
Felt BT, Beard JL, Schallert T, Shao J, Aldridge JW, Connor JR, et al. Persistent neurochemical and behavioral abnormalities in adulthood despite early iron supplementation for perinatal iron deficiency anemia in rats. Behavioural brain Res. 2006;171:261–70.
Ortiz E, Pasquini JM, Thompson K, Felt B, Butkus G, Beard J, et al. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res. 2004;77:681–9.
Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophrenia Res. 2006;85:245–53.
Young KA, Manaye KF, Liang C-L, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry. 2000;47:944–53.
Mighdoll MI, Tao R, Kleinman JE, Hyde TM. Myelin, myelin-related disorders, and psychosis. Schizophrenia Res. 2015;161:85–93.
Hutcheson NL, Clark DG, Bolding MS, White DM, Lahti AC. Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res. 2014;221:6–12.
This work was supported by the National Institutes of Health (R01MH108962 to ML and R01EB027087 to AS) and the Radiology Department at the NYU Grossman School of Medicine. We acknowledge our participants for their contribution. We thank Research Match and NAMI for supporting our recruitment efforts.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sui, Y.V., McKenna, F., Bertisch, H. et al. Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms. Mol Psychiatry 27, 5144–5153 (2022). https://doi.org/10.1038/s41380-022-01740-2